Domperidone Price in China

 

  • China: 104,792 USD/MT

 

In the second quarter of 2023, the price of the domperidone in China reached 104,792 USD/MT by June.

The latest report by IMARC Group, titled "Domperidone Pricing Report 2024: Price Trend, Chart, Market Analysis, News, Demand, Historical and Forecast Data," provides a thorough examination of domperidone prices. This report delves into globally, presenting a detailed analysis, along with informative price chart. Through comprehensive price analysis, the report sheds light on the key factors influencing these trends. Additionally, it includes historical data to offer context and depth to the current pricing landscape. The report also explores the demand, analyzing how it impacts market dynamics. To aid in strategic planning, the price forecast section provides insights into price forecast, making this report an invaluable resource for industry stakeholders.

 

Report Offering:

  • Monthly Updates: Annual Subscription
  • Quarterly Updates: Annual Subscription
  • Biannually Updates: Annual Subscription

 

The study delves into the factors affecting domperidone price variations, including alterations in the cost of raw materials, the balance of supply and demand, geopolitical influences, and sector-specific developments.

The report also incorporates the most recent updates from the market, equipping stakeholders with the latest information on market fluctuations, regulatory modifications, and technological progress. It serves as an exhaustive resource for stakeholders, enhancing strategic planning and forecast capabilities.

Request For a Sample Copy of the Report: https://www.imarcgroup.com/domperidone-pricing-report/requestsample

Domperidone Price Trend- Last Quarter

Domperidone is a dopamine antagonist commonly used to relieve nausea, vomiting, and gastric motility disorders by enhancing gastrointestinal peristalsis. It works by blocking dopamine receptors in the gut and the chemoreceptor trigger zone (CTZ) of the brain, which are responsible for controlling vomiting. Unlike other antiemetics, domperidone does not readily cross the blood-brain barrier, minimizing the risk of central nervous system side effects, such as sedation or movement disorders, often associated with dopamine blockers. This makes it a preferred choice for certain patients who are sensitive to such effects. Also, domperidone is sometimes used to promote lactation in breastfeeding mothers, as it increases prolactin levels by inhibiting dopamine's suppressive action on the pituitary gland.

Domperidone Industry Analysis

The growth of the global domperidone market is driven by an increasing prevalence of gastrointestinal disorders, such as gastroparesis and dyspepsia leading to a higher demand for effective treatments. Concurrent with this, rising awareness of the need for better gastrointestinal health management, particularly in aging populations, is further contributing to the growing market demand.

Moreover, the ongoing rise in chronic conditions like diabetes, which is often associated with delayed gastric emptying, drives the use of domperidone to alleviate symptoms related to diabetic gastroparesis, creating a positive outlook for market expansion. In confluence with this, manufacturers are now focusing on diversifying suppliers and increasing local API production to avoid future shortages, which is strengthening the market growth.

Additionally, the growing use of domperidone as a galactagogue to enhance milk production in lactating women, especially in regions where breastfeeding is highly encouraged, is providing an impetus to market growth. Besides this, significant advancements in pharmaceutical formulations, offering more patient-friendly options such as extended-release tablets, have expanded domperidone's reach among patients. However, pharmaceutical companies are developing new formulations, such as extended-release tablets and liquid suspensions, to improve patient compliance and broaden the market for domperidone. These advancements are particularly targeting pediatric and elderly populations.

Furthermore, regulatory approvals across various countries have opened new markets, facilitating broader usage and distribution of the drug. Increasing healthcare expenditure, especially in developing economies, supports market expansion as accessibility to medications like domperidone improves. Apart from this, the trend towards self-medication in certain regions, particularly with over-the-counter (OTC) versions of domperidone for nausea and vomiting, is fueling consumer demand.

Regional Price Analysis:

  • Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand
  • Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece
  • North America: United States and Canada
  • Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru
  • Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco

Note: The current country list is selective, detailed insights into additional countries can be obtained for clients upon request.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145